3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Thyroid Neoplasms
5
Thyroid Cancer, Papillary
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Diseases
1
Thyroid Carcinoma, Anaplastic
1
Sexual Dysfunction, Physiological
1
Neoplasms
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Carcinoma, Medullary
1
Cachexia-Anorexia Syndrome
1
Breast Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Adenocarcinoma, Follicular
1
Interventions
Oxaliplatin
18
Surveys and Questionnaires
15
Fluorouracil
15
Capecitabine
13
Leucovorin
12
Blood Specimen Collection
11
Irinotecan
10
Standard of Care
7
Cisplatin
7
Endoscopic Mucosal Resection
6
atezolizumab
5
Specimen Handling
5
Radiotherapy
5
Educational Status
5
Drug Therapy
5
Docetaxel
5
S 1 (combination)
4
Radiosurgery
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Interviews as Topic
4
Gemcitabine
4
Everolimus
4
Colonoscopy
4
Biopsy
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
apatinib
3
Remote Patient Monitoring
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastrointestinal Neoplasms
×
selpercatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled